Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

PresbV Tears: non-invasive solution for presbyopia

Poster Details

First Author: L. Vejarano COLOMBIA

Co Author(s):                        

Abstract Details

Purpose:

To evaluate the predictability, reproducibility, efficacy, reliability and Safety of this innovative NON-invasive treatment for ameliorating presbyopia.

Setting:

Anterior Segment Department, Fundación Oftalmológica Vejarano, Popayán, Cauca, Colombia, South America.

Methods:

Prospective study of the results in Dynamic Pseudoaccommodation and real Accommodation (subjective and objectively (with HD Analyzer, iTracey, UBM, OCT and Scheimpflug)), defocus curve, refraction, visual acuity corrected and uncorrected for far and near distance, refractive change, pupil size and dynamism (Dynamic Visual Lab Photopic and Scotopic), endothelial cell count, Schirmer test, IOP, Keratometry, Pachymetry, Contrast Sensibility and ACD using the PresbV Tears only one drop in each eye (not MONOVISION).

Results:

20 Presbyopic patients, 9 Emetropes, 5 postLasik in their youth and 6 post PresbV LASIK; the average age was 49,65 yo within a range of 41 to 57, the measurements were taken previously, 1/2, 1, 2, 3, 4 and 5 hours later and 1 week and 1 month after. Improving one line for Far and three for Near, 20/20 Intermediate, mild decrease of Pupil Size but active with light conditions, first hour mild Myopic shift, No changes in Endothelial Cell count and lacrimal film, decrease IOP, the Keratometry get steep and shallowing of ACD typically showing the accommodation stimulus.

Conclusions:

This is a promising, NON-invasive and adjuvant solution for Presbyopia patients; generating enough independence of glasses for the most activities in the normal life of the patients with no risks neither secondary effects, incredible improving in intermediate vision (20/20).

Financial Disclosure:

One or more of the authors gains financially from product or procedure presented, One or more of the authors has significant investment interest in a company producing, developing or supplying product or procedure presented

Back to Poster listing